Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO? (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
Company Announcement
- DARZALEX?FASPRO??(daratumumab and hyaluronidase-fihj) approved by U.S. FDA as the first and only therapy for newly diagnosed Light-chain (AL) amyloidosis
- Accelerated approval of DARZALEX?FASPRO-based combination regimen supported by the Phase 3 ANDROMEDA (AMY3001) study
- Genmab to receive USD 30 million milestone payment on first commercial sale